Market open · Delayed intraday data · 1:12 PM ET
Last update: Nov 19, 2026, 1:02 PM ET
Revvity, Inc.
$152.83▲ 0.26% today
Market Open

Why Revvity, Inc. (RVTY) stock moved

Latest session▲ 3.1% · Nov 18, 2026 close

Why Revvity, Inc. (RVTY) rose 3.1% on November 18, 2026

Revvity, Inc. (RVTY) rose 3.1% on November 18, 2026, closing at $152.43 versus $147.79 the prior session (close-to-close, from daily closes). After the company presented at the Jefferies Global Healthcare Conference 2026, discussing company strategy and outlook. Source: FMP price data; BestStocks detection.

Updated
Prior close
$147.79
Nov 18, 2026 close
$152.43
Change (close-to-close)
+$4.64
+3.14%
As first detected · Nov 18, 2026, 4:45 PM ET

Revvity, Inc. (RVTY) moved +3.93% from $146.66 to $152.43 on 2026-11-18 after the company presented at the Jefferies Global Healthcare Conference 2026, discussing company strategy and outlook.

What to watch next: RVTY earnings are scheduled for 2026-02-01 (date not yet confirmed), with consensus EPS estimate of $1.61.

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved RVTY

  1. −3.6%Revvity is trading 2.56% lower at $150.44, driven by a combination of broader market caution in tech/AI-adjacent sectors and profit-taking following a strong recent run, according to the web catalyst analysis.
  2. +2.8%After beating Q3 expectations on 2026-11-03.
  3. −5.4%After the company reported Q3 EPS of $1.38, beating consensus estimate of $1.30 by 6.15%, and raised 2026 guidance.
  4. +7.8%Volume data are not yet reliable at 55 minutes into the session.
  5. −3.4%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  6. −5.3%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  7. +3.4%36% year-to-date, according to Yahoo Finance.
  8. −2.6%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  9. +3.8%Following analyst upgrades and positive earnings revisions.
  10. −2.5%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  11. +6.0%Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes: WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population [2026-09-24]
  12. +4.0%Improving order pipelines, per Zacks.
  13. +9.1%Revvity surged 9.1% on September 15, 2026, driven by major analyst price-target hikes from KeyBanc (to $165) and Baird (to $144), citing robust AI-driven screening demand in life science tools. Read the September 15, 2026 analysis →
  14. +3.4%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  15. −2.5%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.

Revvity, Inc. (RVTY) shares rose 0.3% to $152.83 as of November 19, 2026, a slight gain from the prior close of $152.43. BestStocks flagged the session as a major change for RVTY. Below, we break down what changed for RVTY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

RVTY climbed 0.3% to $152.83

Revvity is trading 2.56% lower at $150.44, driven by a combination of broader market caution in tech/AI-adjacent sectors and profit-taking following a strong recent run, according to the web catalyst analysis. The stock has pulled back after trading near its 52-week high of $171.74 earlier in November, following Q3 earnings (reported Nov 3) that beat expectations with $729M revenue and $1.38 adjusted EPS, and an Investor Day on Nov 13. Volume is running at 0.58x the expected level at this point in the session, below average. Revvity earnings scheduled for February 1, 2027 (consensus EPS estimate: $1.61); also monitor broader tech sector sentiment and Nasdaq direction this week.

This summary describes the catalyst and move as first detected on Nov 16, 2026, 12:42 PM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
ValuationWeak confidence
Rel. volume
0.2×
Below Avg
Vs peers
—
No comparable peers
Market cap
$17.1B
New York Stock Exchange
Analyst target
$151
-0.9% vs price
Price chart
Oct 19 – Nov 19
VNFVENVNV$147$157$166Oct 19Oct 27Nov 4Nov 11Nov 19
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Revvity, Inc. investors

For Revvity, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.3% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $151.43, implying -0.9% downside from $152.83. BestStocks rates the overall signal quality weak (28/100). With earnings roughly 74 days out, the next report is the most likely near-term test of the move.

RVTY price reaction

RVTY last traded at $152.83, up $0.40 (+0.26%) from the previous close of $152.43. The session traded on 0.2× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $147.79 and $165.78, and it currently sits about 28% of the way up that band.

Bullish and bearish analyst opinions on Revvity, Inc. (RVTY)

The consensus analyst price target on Revvity, Inc. (RVTY) is $151.43, 0.9% below the recent $152.83. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RVTY line up.

The bullish case

  • The Street's most bullish target is $200.00 (+30.9%).
  • Positive 0.3% session move.
  • Positive price momentum.

The bearish case

  • The consensus analyst price target of $151.43 sits 0.9% below the recent $152.83, so the average target sees limited room to run.
  • The most bearish analyst target is $115.00 (-24.8%).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $151-0.9%
= 8 maintains
RBC Capital maintained Sector Perform · 2026-11-04
SEC filings watch
8-K2026-11-13
Material event — review for impact
high
10-Q2026-11-10
Quarterly financial results
medium
8-K2026-11-03
Material event — review for impact
high
10-Q2026-08-11
Quarterly financial results
medium
Peer context
RVTY+0.3%

Previous notable changes for RVTY

News2026-11-13-1.7%
Revvity hosts 2026 Investor Day to showcase Life Sciences, Diagnostics portfolio and scientific intelligence strategy.
Filings2026-11-10-1.0%
Revvity, Inc. (RVTY) filed a 10-Q on November 10, 2026, covering its most recent quarter.
Activity2026-11-03+7.8%via zacks.com ↗
Revvity topped Q3 2026 earnings and revenue estimates, according to Zacks and Investor's Business Daily, beating what was characterized as 'elevated investor expectations.' The stock surged 11.44% intraday from $151.60 to $168.95. Volume data are not yet reliable at 55 minutes into the session.
Material / Earnings2026-11-02-3.4%
Revvity, Inc. (RVTY) moved -5.26% from $160.07 to $151.65 on November 2, 2026. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.5x the 5-day average, modestly elevated.

In-depth RVTY event analyses

Permanent, dated analyses of RVTY's most significant sessions.
Upcoming catalysts & outlook
Next earnings
2027-02-01 (est.)
in 74 days
10-Q Filing (est.)
2027-02-09
Medium impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
Low
from change events

Frequently asked questions about RVTY

Why did Revvity, Inc. (RVTY) stock move?

Revvity, Inc. (RVTY) rose 3.1% on November 18, 2026, closing at $152.43 versus $147.79 the prior session (close-to-close, from daily closes). After the company presented at the Jefferies Global Healthcare Conference 2026, discussing company strategy and outlook. Source: FMP price data; BestStocks detection.

How much did RVTY stock rise?

RVTY gained 0.26% ($0.40) versus the prior close of $152.43, last trading at $152.83 on 0.2× average volume.

When is Revvity, Inc.'s next earnings date?

RVTY's next earnings report is estimated for 2027-02-01 — about 74 days away.

What is the analyst price target for RVTY?

The consensus analyst price target for RVTY is $151.43, about 0.9% below the current $152.83. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 0 downgrades.

How BestStocks tracks RVTY

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RVTY-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for RVTY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.